Metabolic Syndrome and Triple-Negative Breast Cancer: A New Paradigm
Triple-negative breast cancers (TNBCs) are aggressive tumors with poor prognosis compared to other breast cancer subtypes. The evidence linking TNBC with the metabolic syndrome, which consists of central obesity, insulin resistance, impaired glucose tolerance, dyslipidemia, and hypertension, has eme...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | International Journal of Breast Cancer |
| Online Access: | http://dx.doi.org/10.1155/2012/809291 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550981532909568 |
|---|---|
| author | Andrew A. Davis Virginia G. Kaklamani |
| author_facet | Andrew A. Davis Virginia G. Kaklamani |
| author_sort | Andrew A. Davis |
| collection | DOAJ |
| description | Triple-negative breast cancers (TNBCs) are aggressive tumors with poor prognosis compared to other breast cancer subtypes. The evidence linking TNBC with the metabolic syndrome, which consists of central obesity, insulin resistance, impaired glucose tolerance, dyslipidemia, and hypertension, has emerged from clinical studies and experiments using cell lines and mouse models. Epidemiological studies have associated abdominal obesity with increased incidence of TNBC. Additionally, insulin resistance, dyslipidemia, and hypertension are associated with increased incidence of breast cancer across all subtypes. The insulin-leptin-adiponectin axis has been implicated mechanistically in breast cancer tumorigenesis. Specifically, increased leptin and decreased adiponectin levels disrupt homeostatic signaling pathways involved in cell proliferation, survival, cell-cycle regulation, and angiogenesis. Insulin, insulin-like growth factor I (IGF-I), and epidermal growth factor receptor (EGFR) may mediate interactions between these two hormones. Further research will facilitate the development of targeted therapeutics and programs to modify lifestyle factors to modulate the insulin-leptin-adiponectin axis for TNBC. |
| format | Article |
| id | doaj-art-78e0fc92dac3406c98611b49eecb43cf |
| institution | Kabale University |
| issn | 2090-3170 2090-3189 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Breast Cancer |
| spelling | doaj-art-78e0fc92dac3406c98611b49eecb43cf2025-02-03T06:05:22ZengWileyInternational Journal of Breast Cancer2090-31702090-31892012-01-01201210.1155/2012/809291809291Metabolic Syndrome and Triple-Negative Breast Cancer: A New ParadigmAndrew A. Davis0Virginia G. Kaklamani1Cancer Genetics Program, Division of Hematology/Oncology, Department of Medicine and Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USACancer Genetics Program, Division of Hematology/Oncology, Department of Medicine and Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USATriple-negative breast cancers (TNBCs) are aggressive tumors with poor prognosis compared to other breast cancer subtypes. The evidence linking TNBC with the metabolic syndrome, which consists of central obesity, insulin resistance, impaired glucose tolerance, dyslipidemia, and hypertension, has emerged from clinical studies and experiments using cell lines and mouse models. Epidemiological studies have associated abdominal obesity with increased incidence of TNBC. Additionally, insulin resistance, dyslipidemia, and hypertension are associated with increased incidence of breast cancer across all subtypes. The insulin-leptin-adiponectin axis has been implicated mechanistically in breast cancer tumorigenesis. Specifically, increased leptin and decreased adiponectin levels disrupt homeostatic signaling pathways involved in cell proliferation, survival, cell-cycle regulation, and angiogenesis. Insulin, insulin-like growth factor I (IGF-I), and epidermal growth factor receptor (EGFR) may mediate interactions between these two hormones. Further research will facilitate the development of targeted therapeutics and programs to modify lifestyle factors to modulate the insulin-leptin-adiponectin axis for TNBC.http://dx.doi.org/10.1155/2012/809291 |
| spellingShingle | Andrew A. Davis Virginia G. Kaklamani Metabolic Syndrome and Triple-Negative Breast Cancer: A New Paradigm International Journal of Breast Cancer |
| title | Metabolic Syndrome and Triple-Negative Breast Cancer: A New Paradigm |
| title_full | Metabolic Syndrome and Triple-Negative Breast Cancer: A New Paradigm |
| title_fullStr | Metabolic Syndrome and Triple-Negative Breast Cancer: A New Paradigm |
| title_full_unstemmed | Metabolic Syndrome and Triple-Negative Breast Cancer: A New Paradigm |
| title_short | Metabolic Syndrome and Triple-Negative Breast Cancer: A New Paradigm |
| title_sort | metabolic syndrome and triple negative breast cancer a new paradigm |
| url | http://dx.doi.org/10.1155/2012/809291 |
| work_keys_str_mv | AT andrewadavis metabolicsyndromeandtriplenegativebreastcanceranewparadigm AT virginiagkaklamani metabolicsyndromeandtriplenegativebreastcanceranewparadigm |